# Hutchison Medipharma Limited clinical trials: 68 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 68 trials with Hutchison Medipharma Limited as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Hutchison Medipharma Limited: 68 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/hutchison-medipharma-limited

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 68
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 68, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 22, 2022 | NCT05509699 | Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer | Hutchison Medipharma Limited | Phase 2 | Completed | Extensive-Stage Small Cell Lung Cancer | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05509699) |
| April 8, 2022 | NCT05318820 | A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers | Hutchison Medipharma Limited | Early phase 1 | Completed | Healthy Subject | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05318820) |
| March 14, 2022 | NCT05277454 | Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT | Hutchison Medipharma Limited | Phase 1 | Unknown | Advanced Malignant Solid Tumors, TGCT | 113 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05277454) |
| December 29, 2021 | NCT05173142 | A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced... | Hutchison Medipharma Limited | Phase 1/2 | Completed | Solid Tumor | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05173142) |
| August 20, 2021 | NCT05015621 | A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma | Hutchison Medipharma Limited | Phase 3 | Unknown | Advanced Neuroendocrine Carcinoma | 194 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05015621) |
| August 20, 2021 | NCT05015608 | Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification | Hutchison Medipharma Limited | Phase 3 | Completed | Non-small Cell Lung Cancer | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05015608) |
| June 11, 2021 | NCT04923945 | Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients | Hutchison Medipharma Limited | Phase 3 | Completed | Non-small Cell Lung Cancer Metastatic | 203 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04923945) |
| June 11, 2021 | NCT04923932 | Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients | Hutchison Medipharma Limited | Phase 2 | Completed | Gastric Cancer, Esophagogastric Junction Disorder | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04923932) |
| April 19, 2021 | NCT04849351 | Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma | Hutchison Medipharma Limited | Phase 2 | Completed | Marginal Zone Lymphoma, Follicular Lymphoma | 178 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04849351) |
| February 15, 2021 | NCT04755088 | Surufatinib Renal Impairment Study | Hutchison Medipharma Limited | Phase 1 | Completed | Renal Impairment | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04755088) |
| February 15, 2021 | NCT04755075 | Surufatinib Hepatic Impairment Study | Hutchison Medipharma Limited | Phase 1 | Completed | Hepatic Impairment | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04755075) |
| November 27, 2020 | NCT04645940 | Fruquintinib Food Effect and Proton Pump Inhibitor Study | Hutchison Medipharma Limited | Phase 1 | Completed | Drug Interaction, Food-drug Interaction | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04645940) |
| September 21, 2020 | NCT04557397 | Fruquintinib CYP3A Inhibitor and Inducer Study | Hutchison Medipharma Limited | Phase 1 | Completed | Drug Drug Interaction | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04557397) |
| August 12, 2020 | NCT04510649 | Surufatinib DDI With a PPI and a CYP3A Inducer | Hutchison Medipharma Limited | Phase 1 | Completed | Healthy | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04510649) |
| May 4, 2020 | NCT04372407 | A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects | Hutchison Medipharma Limited | Phase 1 | Completed | Healthy | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04372407) |
| May 4, 2020 | NCT04372394 | A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects | Hutchison Medipharma Limited | Phase 1 | Completed | Healthy | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04372394) |
| March 26, 2020 | NCT04322539 | A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer | Hutchison Medipharma Limited | Phase 3 | Completed | Metastatic Colorectal Cancer, Metastatic Colon Cancer | 691 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04322539) |
| February 28, 2020 | NCT04290325 | HMPL-453 in Advanced Malignant Mesothelioma | Hutchison Medipharma Limited | Phase 2 | Unknown | Advanced Malignant Mesothelioma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04290325) |
| February 17, 2020 | NCT04272957 | A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms | Hutchison Medipharma Limited | Phase 1 | Unknown | Acute Myeloid Leukemia | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04272957) |
| November 20, 2019 | NCT04169672 | Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors | Hutchison Medipharma Limited | Phase 2 | Completed | Advanced Solid Tumors | 248 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04169672) |
| May 15, 2019 | NCT03951623 | The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients | Hutchison Medipharma Limited | Phase 1 | Completed | Immune Thrombocytopenia (ITP) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03951623) |
| March 13, 2019 | NCT03873532 | A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients | Hutchison Medipharma Limited | Phase 2/3 | Unknown | Biliary Tract Cancer | 298 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03873532) |
| March 4, 2019 | NCT03860948 | A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers | Hutchison Medipharma Limited | Phase 1 | Completed | Bioequivalence | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03860948) |
| March 4, 2019 | NCT03860532 | Phase I Clinical Trial in Healthy Male Volunteers | Hutchison Medipharma Limited | Phase 1 | Completed | Inflammatory Bowel Diseases | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03860532) |
| September 26, 2018 | NCT03684967 | Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC | Hutchison Medipharma Limited | Phase 2 | Withdrawn | Lung Cancer | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03684967) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 2 |
| Phase 1 | 36 |
| Phase 1/2 | 4 |
| Phase 2 | 14 |
| Phase 2/3 | 1 |
| Phase 3 | 11 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 53 |
| Unknown | 9 |
| Terminated | 5 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Neoplasms | 7 |
| Stomach Neoplasms | 4 |
| Colorectal Neoplasms | 4 |
| Neuroendocrine Tumors | 3 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Colitis, Ulcerative | 3 |
| Colonic Neoplasms | 2 |
| Leukemia, Myeloid, Acute | 2 |
| Biliary Tract Neoplasms | 2 |
| Lymphoma, Follicular | 2 |
| Crohn Disease | 1 |
| Small Cell Lung Carcinoma | 1 |
| Hematologic Neoplasms | 1 |
| Breast Neoplasms | 1 |
| Triple Negative Breast Neoplasms | 1 |
| Rectal Neoplasms | 1 |
| Inflammatory Bowel Diseases | 1 |
| Purpura, Thrombocytopenic, Idiopathic | 1 |
| Lung Neoplasms | 1 |
| Glioblastoma | 1 |
| Leukemia, Myelomonocytic, Chronic | 1 |
| Leukemia, Myeloid | 1 |
| Renal Insufficiency | 1 |
| Lymphoma | 1 |
| Motor Activity | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Wholesalers in the United States](https://specstream.ai/data/businesses/wholesalers/united-states)
- [Chicken restaurants in the United States](https://specstream.ai/data/businesses/chicken-restaurants/united-states)
- [Gastroenterology practices in the United States](https://specstream.ai/data/businesses/gastroenterology-practices/united-states)
- [Motels in the United States](https://specstream.ai/data/businesses/motels/united-states)
- [Software development companies in the United States](https://specstream.ai/data/businesses/software-development-companies/united-states)
- [Auto lenders in the United States](https://specstream.ai/data/businesses/auto-lenders/united-states)
